Literature DB >> 17551258

Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II.

Mei-Fang Chen1, Xiu-Mei Xie, Tian-Lun Yang, Yong-Jin Wang, Xiao-Hong Zhang, Bai-Lin Luo, Yuan-Jian Li.   

Abstract

Previous investigations have demonstrated that angiotensin (Ang) II induces inflammatory reactions and asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor, might be a novel inflammatory factor. Endothelial cell activation was induced by incubation with Ang II or ADMA. Incubation with Ang II (10(-6) M) for 24 h elevated the levels of ADMA and decreased the levels of nitrite/nitrate concomitantly with a significant increase in the expression of protein arginine methyltransferase and a decrease in the activity of dimethylarginine dimethylaminohydrolase (DDAH). Exposure to Ang II (10(-6) M for 24 h) also enhanced intracellular ROS elaboration and the levels of tumor necrosis factor (TNF)-alpha and interleukin (IL)-8, upregulated chemokine receptor CXCR2 mRNA expression, increased adhesion of endothelial cells to monocytes and induced a significant increase in the activity of nuclear factor (NF)-kappaB, which was attenuated by pretreatment with the Ang II receptor blocker losartan (1, 3 and 10 muM). Exogenous ADMA (30 microM) also increased ROS generation and the levels of TNF-alpha and IL-8, decreased the levels of nitrite/nitrate, upregulated CXCR2 gene expression, increased endothelial cell binding with monocytes and activated the NF-kappaB pathway, which was inhibited by pretreatment with losartan or L-arginine. These data suggest that ADMA is a potential proinflammatory factor and may be involved in the inflammatory reaction induced by Ang II. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17551258     DOI: 10.1159/000103284

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  17 in total

1.  Effect of AT1 receptor blockade on intermittent hypoxia-induced endothelial dysfunction.

Authors:  Noah J Marcus; Nathan R Philippi; Cynthia E Bird; Yu-Long Li; Harold D Schultz; Barbara J Morgan
Journal:  Respir Physiol Neurobiol       Date:  2012-06-21       Impact factor: 1.931

Review 2.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables.

Authors:  Christopher S Wilcox
Journal:  Hypertension       Date:  2012-01-03       Impact factor: 10.190

4.  The ADMA-Metformin Hypothesis: Linking the Cardiovascular Consequences of the Metabolic Syndrome and Type 2 Diabetes.

Authors:  William H Bestermann
Journal:  Cardiorenal Med       Date:  2011-10-04       Impact factor: 2.041

5.  Impaired endothelial function and microvascular asymmetrical dimethylarginine in angiotensin II-infused rats: effects of tempol.

Authors:  Dan Wang; Zaiming Luo; Xiaoyan Wang; Pedro A Jose; John R Falck; William J Welch; Shakil Aslam; Tom Teerlink; Christopher S Wilcox
Journal:  Hypertension       Date:  2010-09-13       Impact factor: 10.190

6.  Asymmetric dimethylarginine in angiotensin II-induced hypertension.

Authors:  Jennifer M Sasser; Natasha C Moningka; Mark W Cunningham; Byron Croker; Chris Baylis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-16       Impact factor: 3.619

7.  Regulation of oxygen utilization by angiotensin II in chronic kidney disease.

Authors:  Aihua Deng; Tong Tang; Prabhleen Singh; Chen Wang; Joe Satriano; Scott C Thomson; Roland C Blantz
Journal:  Kidney Int       Date:  2008-09-24       Impact factor: 10.612

8.  Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation.

Authors:  Juxian Wang; Limin Chen; Sarmistha Halder Sinha; Zhongjie Liang; Huifang Chai; Sakthivel Muniyan; Yu-Wei Chou; Chao Yang; Leilei Yan; You Feng; Keqin Kathy Li; Ming-Fong Lin; Hualiang Jiang; Yujun George Zheng; Cheng Luo
Journal:  J Med Chem       Date:  2012-09-12       Impact factor: 7.446

Review 9.  Cellular ADMA: regulation and action.

Authors:  Tom Teerlink; Zaiming Luo; Fredrik Palm; Christopher S Wilcox
Journal:  Pharmacol Res       Date:  2009-08-12       Impact factor: 7.658

10.  Losartan inhibits monocytic adhesion induced by ADMA via downregulation of chemokine receptors in monocytes.

Authors:  Mei-Fang Chen; Yuan-Jian Li; Tian-Lun Yang; Bin Lou; Xiu-Mei Xie
Journal:  Eur J Clin Pharmacol       Date:  2009-01-22       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.